• Skip to primary navigation
  • Skip to main content
  • Skip to footer

TVM Capital Life Science Venture Capital

Investing in Life Science Innovation

  • About Us
    • Partners
  • Team
  • Senior Advisors
  • Portfolio
  • Funding Request
  • News
  • Events
  • ESG Policy
  • Contact

Sarkana Pharma, Inc.

  • Home
  • About Us
  • Team
  • Senior Advisors
  • Portfolio
  • News
  • Events
  • ESG Policy
  • Contact

Sarkana Pharma, Inc.

Investment: 2021
Visit Website

Sarkana Pharma, Inc. plans to develop, to proof-of-concept, an anti-inflammatory biologic with the potential to treat certain types of auto-immune diseases, including systemic lupus erythematosus (SLE) also known as Lupus. It was originally discovered through one of Eli Lilly and Company’s (Lilly) research and development programs. The Lupus Foundation of America estimates that 1.5 million Americans, and at least five million people worldwide, have a form of lupus. Lupus strikes mostly women of childbearing age. However, men, children, and teenagers can also develop lupus.

  • in

Copyright © 2023 · TVM Capital Life Science Venture Capital · ESG Disclosure · Privacy Policy · Contact